Please assess the completion status of the following clinical trial:

Trial Title: Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with FRDA confirmed by genetic testing with 2 expanded Guanine-adenine-adenine repeats~* Females who are not pregnant or breast feeding, and who do not intend to become pregnant. Females of child-bearing potential must use a reliable method of contraception and must provide a negative urine pregnancy test at screening~* Stable doses of all medications, vitamins and supplements for 30 days prior to study entry and for the duration of the study~* Parent/guardian permission (informed consent) and child assent~Exclusion Criteria:~* Any unstable illness that in the investigator's opinion precludes participation in this study~* Use of any investigational product within 30 days prior to enrollment~* Subjects with a history of substance abuse~* Presence of clinically significant cardiac disease~* History of hypersensitivity to IFN-g or E. coli derived products~* Presence of severe renal disease or hepatic disease~* Clinically significant abnormal White blood cell count, hemoglobin or platelet count~* Any subject planning a scheduled surgical procedure during the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Interferon Gamma-1b (ACTIMMUNE) (Type: EXPERIMENTAL): All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).